Neuroone Medical Technologies (NMTC) EBITDA Margin (2011 - 2026)

Neuroone Medical Technologies has disclosed EBITDA Margin across 12 years of filings, most recently posting 128.74% for Q1 2026.

• Quarterly EBITDA Margin rose 6455.0% year-over-year to 128.74% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 80.1% (up 3415.0% YoY) and the FY2025 annual result came in at 46.46%, up 29780.0% from the prior year.
• EBITDA Margin declined to 128.74% in Q1 2026, from 59.02% in the prior quarter.
• Across five years, EBITDA Margin topped out at 52.26% in Q4 2024 and bottomed at 8616.29% in Q2 2022.
• The 5-year median for EBITDA Margin is 346.8% (2023), against an average of 1454.47%.
• Year-over-year, EBITDA Margin plunged 104696 bps in 2022 and surged 805902 bps in 2023.
• Neuroone Medical Technologies' EBITDA Margin stood at 1557.31% in 2022, then jumped by 78 bps to 346.8% in 2023, then surged by 115 bps to 52.26% in 2024, then tumbled by 213 bps to 59.02% in 2025, then sank by 118 bps to 128.74% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 128.74%, 59.02%, and 50.02% for Q1 2026, Q4 2025, and Q3 2025 respectively.